- Home
- DXR vs FGEN Comparison
DXR vs FGEN Comparison
Compare DXR & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- FGEN
- Stock Information
- Founded
- DXR 1970
- FGEN 1993
- Country
- DXR United States
- FGEN United States
- Employees
- DXR N/A
- FGEN N/A
- Industry
- DXR Medical/Dental Instruments
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- DXR Health Care
- FGEN Health Care
- Exchange
- DXR Nasdaq
- FGEN Nasdaq
- Market Cap
- DXR 40.3M
- FGEN 33.5M
- IPO Year
- DXR N/A
- FGEN 2014
- Fundamental
- Price
- DXR $7.77
- FGEN $0.31
- Analyst Decision
- DXR Strong Buy
- FGEN Strong Buy
- Analyst Count
- DXR 1
- FGEN 1
- Target Price
- DXR $25.00
- FGEN $10.00
- AVG Volume (30 Days)
- DXR 5.2K
- FGEN 899.4K
- Earning Date
- DXR 01-01-0001
- FGEN 05-05-2025
- Dividend Yield
- DXR N/A
- FGEN N/A
- EPS Growth
- DXR 86.16
- FGEN N/A
- EPS
- DXR 0.11
- FGEN N/A
- Revenue
- DXR $119,714.00
- FGEN $29,621,000.00
- Revenue This Year
- DXR N/A
- FGEN $232.81
- Revenue Next Year
- DXR N/A
- FGEN $9.16
- P/E Ratio
- DXR $71.76
- FGEN N/A
- Revenue Growth
- DXR N/A
- FGEN N/A
- 52 Week Low
- DXR $6.55
- FGEN $0.18
- 52 Week High
- DXR $10.00
- FGEN $1.74
- Technical
- Relative Strength Index (RSI)
- DXR 49.33
- FGEN 48.08
- Support Level
- DXR $7.35
- FGEN $0.27
- Resistance Level
- DXR $7.98
- FGEN $0.32
- Average True Range (ATR)
- DXR 0.43
- FGEN 0.03
- MACD
- DXR -0.00
- FGEN 0.01
- Stochastic Oscillator
- DXR 52.94
- FGEN 86.28
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.